156 related articles for article (PubMed ID: 38924571)
1. The therapeutic potential of indole hybrids, dimers, and trimers against drug-resistant ESKAPE pathogens.
Qiongxian Y; Jun D; Zhenfeng Z; Tongyou L; Zhicong T; Zhenyou T
Arch Pharm (Weinheim); 2024 Jun; ():e2400295. PubMed ID: 38924571
[TBL] [Abstract][Full Text] [Related]
2. Current scenario of quinolone hybrids with potential antibacterial activity against ESKAPE pathogens.
Gao J; Hou H; Gao F
Eur J Med Chem; 2023 Feb; 247():115026. PubMed ID: 36577217
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital.
Pandey R; Mishra SK; Shrestha A
Infect Drug Resist; 2021; 14():2201-2212. PubMed ID: 34163185
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
[TBL] [Abstract][Full Text] [Related]
5. Quantifying the Evolutionary Conservation of Genes Encoding Multidrug Efflux Pumps in the ESKAPE Pathogens To Identify Antimicrobial Drug Targets.
Brooks LE; Ul-Hasan S; Chan BK; Sistrom MJ
mSystems; 2018; 3(3):. PubMed ID: 29719870
[TBL] [Abstract][Full Text] [Related]
6. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of medicinal plants against ESKAPE: An update.
Bhatia P; Sharma A; George AJ; Anvitha D; Kumar P; Dwivedi VP; Chandra NS
Heliyon; 2021 Feb; 7(2):e06310. PubMed ID: 33718642
[TBL] [Abstract][Full Text] [Related]
8. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Resistance in ESKAPE Pathogens.
De Oliveira DMP; Forde BM; Kidd TJ; Harris PNA; Schembri MA; Beatson SA; Paterson DL; Walker MJ
Clin Microbiol Rev; 2020 Jun; 33(3):. PubMed ID: 32404435
[TBL] [Abstract][Full Text] [Related]
10. Coping with the ESKAPE pathogens: Evolving strategies, challenges and future prospects.
Aloke C; Achilonu I
Microb Pathog; 2023 Feb; 175():105963. PubMed ID: 36584930
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Antibacterial Effects of Matrix-Induced Silver Ions against Antibiotic-Resistant ESKAPE Pathogens.
Huang YC; Yang TY; Chen BX; Kung JC; Shih CJ
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832878
[TBL] [Abstract][Full Text] [Related]
12. Foodborne ESKAPE Biofilms and Antimicrobial Resistance: lessons Learned from Clinical Isolates.
Patil A; Banerji R; Kanojiya P; Saroj SD
Pathog Glob Health; 2021 Sep; 115(6):339-356. PubMed ID: 33851566
[TBL] [Abstract][Full Text] [Related]
13. Antarctic Marine Bacteria as a Source of Anti-Biofilm Molecules to Combat ESKAPE Pathogens.
Artini M; Papa R; Vrenna G; Trecca M; Paris I; D'Angelo C; Tutino ML; Parrilli E; Selan L
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887257
[TBL] [Abstract][Full Text] [Related]
14. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
Ma YX; Wang CY; Li YY; Li J; Wan QQ; Chen JH; Tay FR; Niu LN
Adv Sci (Weinh); 2020 Jan; 7(1):1901872. PubMed ID: 31921562
[TBL] [Abstract][Full Text] [Related]
15. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
[TBL] [Abstract][Full Text] [Related]
16. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
Saha U; Gondi R; Patil A; Saroj SD
Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis on Antimicrobial Resistance Trends and Prevalence of β-lactamases in
Nasser M; Palwe S; Bhargava RN; Feuilloley MGJ; Kharat AS
Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33096921
[TBL] [Abstract][Full Text] [Related]
18. Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.
Jadimurthy R; Mayegowda SB; Nayak SC; Mohan CD; Rangappa KS
Biotechnol Rep (Amst); 2022 Jun; 34():e00728. PubMed ID: 35686013
[TBL] [Abstract][Full Text] [Related]
19. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.
Mulani MS; Kamble EE; Kumkar SN; Tawre MS; Pardesi KR
Front Microbiol; 2019; 10():539. PubMed ID: 30988669
[TBL] [Abstract][Full Text] [Related]
20. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
Behroozian S; Svensson SL; Davies J
mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
